FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016943903> ?p ?o ?g. }

• W2016943903 endingPage "697" @default.
• W2016943903 startingPage "681" @default.
• W2016943903 abstract "Journal of the American Geriatrics SocietyVolume 7, Issue 9 p. 681-697 Article A CRITICAL APPRAISAL OF ORAL HYPOGLYCEMIC AGENTS† Thomas Hodge McGavack M.D., Thomas Hodge McGavack M.D. Veterans Administration Center, Martinsburg, West VirginiaSearch for more papers by this author Thomas Hodge McGavack M.D., Thomas Hodge McGavack M.D. Veterans Administration Center, Martinsburg, West VirginiaSearch for more papers by this author First published: September 1959 https://doi.org/10.1111/j.1532-5415.1959.tb00952.x † The studies on metahexamide referred to in this paper were aided by funds from the Clinical Studies Division, Research Service, Veterans Administration, Washington, D. C. through a V.A. Cooperative Diabetes Study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Forsham, P. H.: (Chairman, Panel discussion) Chemical treatment of diabetes, 40th Meeting of The Endocrine Society, San Francisco, California, June 21, 1958. 2Stetten, ***DeW., Jr.: The endocrine regulation of carbohydrate metabolism, J. A. M. A. 132: 373, 1946. 3Stetten, DeW., Jr.: Metabolic effects of insulin, Bull. New York Acad. Med. 29: 466, 1953. 4Stadis, W. C.: Recent advances in insulin research, Diabetes 5: 263, 1956. 5Williams, R. H.; Tyberghein, J. M.; Hyde, P. M., and Nielsen, R. L.: Studies related to the hypoglycemic action of phenethyldiguanide, Metabolism 6: 311, 1957. 6Dobson, H.: Effect of chlorpropamide on intermediary metabolism in human subjects. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Science, Sept. 25–27, 1958. 7Frawley, T. F.; Segal, S.; Camus, M. M., and Foley, J.: A concept of the mechanism of sulfonylurea-induced hypoglycemia based on studies of glucose and pentose disposition in man, Ann. New York Acad. Sc. 71: 81, 1957. 8Berson, S. A., and Yalow, R. S.: Some remarks on the mechanics of action of the sulfonylureas, Diabetes 6: 274, 1957. 9Ashmore, J.; Cahill, G. F., Jr.; Earle, A. S., and Zottu, S.: Studies on the disposition of blood glucose: a comparison of insulin and orinase, Diabetes 7: 1, 1958. 10Purnell, R.; Arai, Y.; Pratt, E.; Hlad, C., Jr., and Elrick, H.: Some observations on the mode of action of Orinase, Metabolism 5: 778, 1956. 11Hawkins, R. D.; Ashworth, M. A., and Haist, R. D.: The effect of BS-55 (carbutamide) on glucose-6-phosphatase, Canad. M. A.J. 74: 972, 1956. 12Miller, M., and Craig, J. W. The use of tolbutamide (Orinase) in the management of various types of diabetes mellitus and studies of possible mechanisms of action, Metabolism 5: 868, 1956. 13Moorhouse, J. A., and Kark, R. M.: Physiologic actions of Orinase and their relationship to the types of diabetes in man, Metabolism 5: 757, 1956. 14Renold, A. E.; Winegrad, A. I.; Froesch, E. R., and Thorn, G. W.: Studies on the site of action of the arylsulfonylureas in man, Metabolism 5: 757, 1956. 15Levine, R., and Sobel, G. W.: The mechanism of action of the sulfonylureas in diabetes mellitus, Diabetes 6: 263, 1957. 16Schambye, P., and Tarding, F.: Insulin- and tolbutamide-induced changes in the glucose output of the liver. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 17Izzo, J. L.: Metabolic effects of sulfonylurea derivatives in selected diabetic subjects. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 18Recant, L., and Fischer, G. L.: Studies on the mechanism of tolbutamide hypoglycemia in animal and human subjects, Ann. New York Acad. Sc. 71: 62, 1957. 19Renold, A. E.; Martin, D. B.; Boshell, B. R., and Thorn, G. W.: Studies on the site of action of arylsulfonylureas in man. II., Ann. New York Acad. Sc. 71: 71, 1957. 20Moorhouse, J. A.; Kark, R. M., and Gellman, D. D.: Effects of tolbutamide and insulin on fructose and glucose metabolism in diabetes mellitus, Ann. New York Acad. Sc. 71: 97, 1957. 21Goetz, F. C.; Gilbertson, A. S., and Josephson, V.: Acute effects of Orinase on peripheral glucose utilization, Metabolism 5: 788, 1956. 22Craig, J. W.; Drucker, W. R.; Miller, M., and Woodward, H., Jr.: A comparison of the influence of tolbutamide and small doses of insulin on the splanchnic output and peripheral uptake of glucose in man. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 23Wick, A. N.; Britton, B., and Brabowski, R.: The action of a sulfonylurea hypoglycemic agent (Orinase) in extrahepatic tissues, Metabolism 5: 739, 1956. 24Vaughan, M.: The effect of tolbutamide on glucose production by the liver in vitro, Ann. New York Acad. Sc. 71: 112, 1957. 25Chen, K. K.; Anderson, R. C., and Maze, N.: Hypoglycemic action of sulfanilamide-cyclopropylthiazole in rabbits and its reversal by alloxan, Proc. Soc. Exper. Biol. & Med. 63: 483, 1946. 26Fritz, I. B.; Morton, J. V.; Weinstein, M., and Levine, R.: Studies on the mechanism of the action of the sulfonylureas, Metabolism 5: 744, 1956. 27Miller, W. L., Jr., Krake, J. J., and Van der Brook, M. J.: Studies on the utilization of uniformly labeled C14-glucose by rats given tolbutamide, J. Pharmacol. & Exper. Therap. 119: 513, 1957. 28Miller, W. L., Jr., Krake, J. J.; Van der Brook, M. J., and Reineke, L. J.: Studies on the absorption, mechanism of action and excretion of tolbutamide in the rat, Ann. New York Acad. Sc. 71: 118, 1957. 29Renold, A. E.; Zahnd, G.; Jeanrenaud, B., and Boshell, B.: Effects of chlorpropamide in vitro compared with those of other hypoglycemic agents. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 30Sass, M. D., and Handelsman, M. B.: The in vivo effect of chlorpropamide on certain liver enzymes in rats. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 31Mirsky, I. A.: The role of insulinase and insulinase inhibitors, Metabolism 5: 138, 1956. 32Mirsky, I. A.; Perisutti, G., and Diengott, D.: The inhibition of insulinase by hypoglycemic sulfonamides, Metabolism 5: 156, 1956. 33Mirsky, I. A.; Perisutti, G., and Gitelson, S.: The role of insulinase in the hypoglycemic response to sulfonylureas, Ann. New York Acad. Sc. 71: 103, 1957. 34Williams, R. H., and Tucker, B. W.: Hypoglycemic actions of tolbutamide and carbutamide, Metabolism 5: 801, 1956. 35Ashmore, J.; Cahill, G. F., Jr., and Earle, A. S.: Studies on the disposition of isotopic glucose in vivo and in vitro under the influence of sulfonylureas, Ann. New York Acad. Sc. 71: 118, 1957. 36Ashmore, J.; Cahill, G. F., Jr., and Hastings, A. B.: Inhibition of glucose-6-phosphatase by hypoglycemic sulfonylureas, Metabolism 5: 774, 1956. 37Kuether, C. A.; Scott, E. G.; Martinez, C.; Lee, H. M., and Pettinga, C. W.: Studies of the effect of carbutamide on glucose-6-phosphatase, Diabetes 6: 26, 1957. 38Stadie, W. C.: Is the metabolism of peripheral tissues affected by the sulfonylureas? (Editorial) Diabetes 7: 61, 1958. 39Loubatières, A.: The mechanism of action of the hypoglycemic sulfonamides: a concept based on investigations in animals and in human beings, Ann. New York Acad. Sc. 71: 192, 1957. 40Schneider, J. A.; Salgado, E. D., and Jaeger, D. A.: The pharmacology of chlorpropamide. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 26–27, 1958. 41Ricketts, H. T.; Wildberber, H. L., and Schmid, H.: Long-term studies of the sulfonylureas in in totally depancreatized dogs, Ann. New York. Acad. Sc. 71: 170, 1957. 42Fajans, S.S.; Louis, L. H.; Seltzer, H. S.; Johnson, R. D.; Gittler, R. D.; Hennes, A. R.; Wajchenberg, B. L.; Ackerman, I. P., and Conn, J. W.: Metabolic effects of arylsulfonylurea compounds in normal men and in diabetic subjects, Metabolism 5: 820, 1956. 43Orgyzlo, M. A., and Harrison, J.: The effect of BS-55 (carbutamide) on pancreatic diabetes following pancreatectomy, Canad. M. A. J. 74: 977, 1956. 44Dulin, W. E., and Johnson, R. L.: Studies concerning the role of the liver in the hypoglycemic response of animals to tolbutamide, Ann. New York Acad. Sc. 71: 177, 1957. 45Wrenshall, G. A., and Best, C. H.: Extractable insulin of the pancreas and effectiveness of oral hypoglycemic sulfonylureas in the treatment of diabetes in man—a comparison, Canad. M. A. J. 74: 968, 1956. 46Beaser, S. B.: The use of Orinase in diabetes, Metabolism 5: 933, 1956. 47Colwell, A. R., Jr., Colwell, J. A., and Colwell, A. R., Sr.: Intrapancreatic perfusion of the antidiabetic sulfonylureas, Metabolism 5: 749, 1956. 48Colwell, A. R., Jr., Colwell, J. A., and Colwell, A. R., Sr.: Perfusion studies with sulfonylureas in dogs, Ann. New York Acad. Sc. 71: 125, 1957. 49Foa, P. O.; Galansino, G.; D'Amico, G., and Kanameishi, D.: A comparison of the metabolic effects of insulin, chlorpropamide and other hypoglycemic substances. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 50Ashworth, M. A., and Haist, R. E.: Some effects of BZ-55 (carbutamide) on the growth of the islets of Langerhans, Canad. M. A. J. 74: 975, 1956. 51Franke, H., and Fuchs, J.: A new antidiabetic principle, Deutsche med. Wchnschr. 80: 1449, 1955. 52Houssay, B. A.; Penhos, J. C.; Urgoiti, E.; Teodosio, N.; Apelbaum, J., and Bowkett, J.: The role of insulin in the action of the hypoglycemic sulfonyl compounds, Ann. New York Acad. Sc. 71: 25, 1957. 53Mortimore, G. E.; DiRaimondo, V. C., and Forsham, P. H.: Metabolic effects of Orinase in diabetes including two cases complicated by other endocrinopathies, Metabolism 5: 840, 1956. 54Loubatières, A.: The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1945, Ann. New York Acad. Sc. 71: 4, 1957. 55Bergenstal, D. M.; Lubs, H. A.; Hallman, L. F., and Schricker, J. A.: Effects of tolbutamide on the diabetes of acromegaly and on the blood sugar in patients with altered endocrine states, Ann. New York Acad. Sc. 71: 215, 1957. 56Campbell, J.: The action of BZ-55 in dogs. Part II. Observations on depancreatized and metahypophyseal diabetic dogs, Canad. M. A. J. 74: 962, 1956. 57Houssay, B. A., and Penhos, J. C.: Action of the hypoglycemic sulfonyl compounds in hypophysectomized, adrenalectomized and depancreatized animals, Metabolism 5: 727, 1956. 58Houssay, B. A.; Penhos, J. C.; Teodosio, N.; Bowkett, J., and Apelbaum, J.: Action of the hypoglycemic sulfonyl compounds in hypophysectomized, adrenalectomized, and depancreatized animals, Ann. New York Acad. Sc. 71: 12, 1957. 59Lang, S., and Sherry, S.: Some effects of Orinase in the rat, Metabolism 5: 733, 1956. 60Mirsky, I. A.: The effect of tolbutamide on the diabetogenic action of somatotropin. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 61McGavack, T. H.; Seegers, W.; Haar, H. O., and Erk, V. O.: The influence of carbutamide on thyroid function in older men and women with diabetes mellitus, Diabetes 6: 80, 1957. 62McGavack, T. H.; Seegers, W.; Haar, H. O.; Enzinger, J., and Erk, V. O.: Thyroid function in diabetes patients as influenced by the sulfonylureas, Ann. New York Acad. Sc. 71: 258, 1957. 63Brown, J., and Solomon, D. H.: Effect of tolbutamide and carbutamide on thyroid function, Metabolism 5: 813, 1956. 64Duncan, G.: Oral hypoglycemic agents (Panel discussion; A. R. Colwell, moderator), Diabetes 7: 53, 1958. 65Fuleihan, F., and Plimpton, C. H.: Experiences with chlorpropamide with reference to its intermittent use. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 66Mirsky, I. A.; Diengott, D., and Dolger, H.: The relation of various variables to the hypoglycemic action of 1-butyl-3-p-tolylsulfonylurea in patients with diabetes mellitus, Metabolism 5: 875, 1956. 67Camerini-Davalos, R.; Marble, A., and Root, H. F.: Clinical experience with Orinase, Metabolism 5: 904, 1956. 68Braverman, A. E.; Drey, N. W., and Sherry, S.: Experience with Orinase in the management of adult diabetes, Metabolism 5: 911, 1956. 69McGavack, T. H.; Seegers, W.; Haar, H., and Erk, V.: Some clinical experiences with the arysulfonylureas in the management of diabetes mellitus, Metabolism 5: 919, 1956. 70Fulmer, H. S.; Dube, A. H., and Lloyd, C. W.: Clinical experience with Orinase, Metabolism 5: 940, 1956. 71Dolger, H.: Clinical experience with Orinase, Metabolism 5: 947, 1956. 72Duncan, G. G.; Joiner, C. L., and Lee, C. T.: Methods of selection of diabetic patients sensitive to sulfonylurea compounds, Metabolism 5: 964, 1956. 73Marble, A., and Camerini-Davalos, R.: Clinical experience with sulfonylurea compounds in diabetes, Ann. New York Acad. Sc. 71: 239, 1957. 74Sugar, S. J. N.: Use of the sulfonylureas in diabetes mellitus, Ann. New York Acad Sc. 71: 256, 1957. 75Beaser, S. B.: Further experience with the use of sulfonylureas in diabetes, Ann. New York Acad. Sc. 71: 264, 1957. 76Dolger, H.: Experience with tolbutamide treatment of five hundred cases of diabetes on an ambulatory basis, Ann. New York Acad. Sc. 71: 275, 1957. 77Lee, C. T., Jr.; Schless, G. L., and Duncan, G. G.: Clinical experiences with chlorpropamide—a double blind study. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 78Bloch, J., and Lenhardt, A.: Advantages and disadvantages in changing diabetic patients from tolbutamide to chlorpropamide. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 79Canessa, I.; Valiente, S., and Mella, I.: Clinical evaluation of chlorpropamide in diabetes mellitus. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 80Skinner, N. S., Jr., and Hill, S. R., Jr.: Studies on the use of chlorpropamide in patients with diabetes mellitus, Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 81Pomeranze, J.: A new hypoglycemic agent (Letter to the Editor), J. Clin. Endocrinol. & Metab. 17: 1011, 1957. 82Bauer, H. G.; Sisler, E. B.; Kao, K. Y. T., and McGavack, T. H.: Some physiologic and therapeutic effects of the hypoglycemic agent, metahexamide, in a group of 13 elderly diabetic men, Metabolism 8: 644, 1959. 83Sugar, S.; Thomas, L., and Tatlier, S.: The use of chlorpropamide in diabetes mellitus in the usual diabetic patients and in the primary and secondary tolbutamide failures. Conference on Chlorpropamide and Diabetes Mellitus, New York Academy of Sciences, Sept. 25–27, 1958. 84Levine, R., and Duncan, G. G. (Editors): Symposium on clinical and experimental effects of sulfonylureas in diabetes mellitus, Metabolism 5: 721–977, 1956. 85Levine, R. (Editor)?: The effects of the sulfonylureas and related compounds in experimental and clinical diabetes, Ann New York Acad. Sc. 71: 1–292, 1957. 86Goldner, M. (Editor): Conference on chlorpropamide and diabetes mellitus, Ann. New York Acad. Sc. (in press). 87Pomeranze, J.; Fujiy, H., and Mouratoff, G. T.: Clinical report of a new hypoglycemic agent, Proc. Soc. Exper. Biol. & Med. 95: 193, 1957. 88Krall, L. P., and Camerini-Davalos, R.: Early clinical evaluation of a new oral non-sulfonylurea hypoglycemic agent, Proc. Soc. Exper. Biol. & Med. 95: 345, 1957. 89Krall, L. P., and Camerini-Davalos, R.: Clinical trials with DBI, a new non-sulfonylurea oral hypoglycemic agent, A. M. A. Arch. Int. Med. 102: 25, 1958. 90McKendry, J. B. R.: Fatal hypoglycemic coma from the use of tolbutamide (Orinase); a case report, Canad. M. A. J. 76: 572, 1957. Volume7, Issue9September 1959Pages 681-697 ReferencesRelatedInformation" @default.
• W2016943903 created "2016-06-24" @default.
• W2016943903 creator A5075638028 @default.
• W2016943903 date "1959-09-01" @default.
• W2016943903 modified "2023-09-25" @default.
• W2016943903 title "A CRITICAL APPRAISAL OF ORAL HYPOGLYCEMIC AGENTS†" @default.
• W2016943903 cites W1963544311 @default.
• W2016943903 cites W1983811733 @default.
• W2016943903 cites W1984614268 @default.
• W2016943903 cites W1985535272 @default.
• W2016943903 cites W1996276598 @default.
• W2016943903 cites W2013557874 @default.
• W2016943903 cites W2016038536 @default.
• W2016943903 cites W2026127532 @default.
• W2016943903 cites W2031813351 @default.
• W2016943903 cites W2032197706 @default.
• W2016943903 cites W2032636140 @default.
• W2016943903 cites W2037813900 @default.
• W2016943903 cites W2040867751 @default.
• W2016943903 cites W2048137577 @default.
• W2016943903 cites W2050460291 @default.
• W2016943903 cites W2050574657 @default.
• W2016943903 cites W2054542420 @default.
• W2016943903 cites W2060333176 @default.
• W2016943903 cites W2072684908 @default.
• W2016943903 cites W2080739245 @default.
• W2016943903 cites W2081226497 @default.
• W2016943903 cites W2090333750 @default.
• W2016943903 cites W2090949819 @default.
• W2016943903 cites W2091753987 @default.
• W2016943903 cites W2112914306 @default.
• W2016943903 cites W2146704602 @default.
• W2016943903 cites W2154805051 @default.
• W2016943903 cites W2312956092 @default.
• W2016943903 cites W2313277082 @default.
• W2016943903 cites W2313769309 @default.
• W2016943903 cites W2317922815 @default.
• W2016943903 cites W2317925688 @default.
• W2016943903 cites W2322908607 @default.
• W2016943903 cites W2323168921 @default.
• W2016943903 cites W2329441884 @default.
• W2016943903 cites W2332034941 @default.
• W2016943903 cites W2333565541 @default.
• W2016943903 cites W2437094778 @default.
• W2016943903 doi "https://doi.org/10.1111/j.1532-5415.1959.tb00952.x" @default.
• W2016943903 hasPublicationYear "1959" @default.
• W2016943903 type Work @default.
• W2016943903 sameAs 2016943903 @default.
• W2016943903 citedByCount "0" @default.
• W2016943903 crossrefType "journal-article" @default.
• W2016943903 hasAuthorship W2016943903A5075638028 @default.
• W2016943903 hasConcept C134018914 @default.
• W2016943903 hasConcept C142724271 @default.
• W2016943903 hasConcept C152541439 @default.
• W2016943903 hasConcept C177713679 @default.
• W2016943903 hasConcept C185592680 @default.
• W2016943903 hasConcept C204787440 @default.
• W2016943903 hasConcept C2777180221 @default.
• W2016943903 hasConcept C2779473830 @default.
• W2016943903 hasConcept C2910525902 @default.
• W2016943903 hasConcept C55493867 @default.
• W2016943903 hasConcept C555293320 @default.
• W2016943903 hasConcept C556039675 @default.
• W2016943903 hasConcept C71924100 @default.
• W2016943903 hasConceptScore W2016943903C134018914 @default.
• W2016943903 hasConceptScore W2016943903C142724271 @default.
• W2016943903 hasConceptScore W2016943903C152541439 @default.
• W2016943903 hasConceptScore W2016943903C177713679 @default.
• W2016943903 hasConceptScore W2016943903C185592680 @default.
• W2016943903 hasConceptScore W2016943903C204787440 @default.
• W2016943903 hasConceptScore W2016943903C2777180221 @default.
• W2016943903 hasConceptScore W2016943903C2779473830 @default.
• W2016943903 hasConceptScore W2016943903C2910525902 @default.
• W2016943903 hasConceptScore W2016943903C55493867 @default.
• W2016943903 hasConceptScore W2016943903C555293320 @default.
• W2016943903 hasConceptScore W2016943903C556039675 @default.
• W2016943903 hasConceptScore W2016943903C71924100 @default.
• W2016943903 hasIssue "9" @default.
• W2016943903 hasLocation W20169439031 @default.
• W2016943903 hasOpenAccess W2016943903 @default.
• W2016943903 hasPrimaryLocation W20169439031 @default.
• W2016943903 hasRelatedWork W135014142 @default.
• W2016943903 hasRelatedWork W1578238918 @default.
• W2016943903 hasRelatedWork W1968326820 @default.
• W2016943903 hasRelatedWork W2011976818 @default.
• W2016943903 hasRelatedWork W2035821584 @default.
• W2016943903 hasRelatedWork W21645691 @default.
• W2016943903 hasRelatedWork W2167153671 @default.
• W2016943903 hasRelatedWork W2582769785 @default.
• W2016943903 hasRelatedWork W320446300 @default.
• W2016943903 hasRelatedWork W4283209696 @default.
• W2016943903 hasVolume "7" @default.
• W2016943903 isParatext "false" @default.
• W2016943903 isRetracted "false" @default.
• W2016943903 magId "2016943903" @default.
• W2016943903 workType "article" @default.